In this episode, I had the pleasure of talking with two Diagnostics Experts.
Irina Korschinek, CEO of Ingenetix and Albert Missbichler, Business Angel specialized in Diagnostics.
Do you want to know answers to all or one of the following questions?
• What is a PCR test?
• Why is it the gold standard of measuring SARS-Cov2 Infections?
• What does a positive or negative test result say?
• Why do false positive and false negative exist. Sho...
Did you know that the successful pipeline of one of the most important pharmaceutical companies in the United States started in Europe, and scientists from Prague played a key role? Did you know that profound expertise in turning deep tech life science into a business, scale it, and go public in the US can be found in Prague since the late 80s of the previous century?
If you want to know which US pharmaceutical companies pipeline st...
Listen to my inspiring conversation with Vassilis Ragoussis about initiatives that support young scientists to become Entrepreneurs.
We dived deep into the entrepreneurial Life Science Eco-System in Oxford, Europe and the United States.
If you want to know what the Eco-System in Oxford is doing for young scientist entrepreneurs, this podcast is for you.
Learn more about Oxford University Biotech Society and Oxford Foundry.
Listen to my conversation with Nicolaj Højer Nielsen about the life of an early-stage investors in Europe.
Nicolaj Højer Nielsen is a serial entrepreneur and business angel who has been building startups since 1999. He focuses on high potential startups and has co-founded and invested in thirteen companies, primarily within IT. He has experience securing funding from all possible sources – friends and family, business angels, VC fun...
We are in the 7th month of the SARS-CoV-2 Pandemic in Europe.
Governments are doing what’s necessary to deal with the situation.
More and more governments are initiating strong measures to control the infection rate with SARS-CoV-2. Israel has announced a second lockdown from September 18 for about three weeks.
There is a lot of coverage of European measures in the local news. Also, a lot of information is published about actions tak...
Do you want to know how to approach Pharma?
Do you want to learn what information is needed to partner a life science project with Pharma?
And how long the process takes?
Then this podcast is for you.
Listen to the expertise of Natalia Novac, Director of Emerging Technologies and Innovation, Eli Lilly.
Natalia has profound experience in strategy, corporate, and business development. She had leading roles at Merck and now Eli Lilly.
In light of the pandemic, the Life Science Industry is changing. One of the positive developments: The industry is moving faster. The necessity of developing diagnostics, therapeutics, and vaccines against this novel viral threat quickly generates a steep learning curve for all of us.
In this episode, I am talking with Peter Llewellyn-Davies, CEO of Apeiron Biologics, how he and his team have set up a clinical phase 2 trial and a 40...
Since the beginning of the SARS-CoV-2 Pandemic, more and more people got interested in the Life Science Industry.
Scientists worldwide have worked together for decades and centuries to solve the world's most severe health problems.
In the last decades, a unique Eco-System of start-ups, investors, industrial partners, and public funding organizations evolved out of this search for finding cures against the world's most comple...
Rumour has it: It takes 10-15 years to bring a new therapy to the patients. Only 1% of all scientific ideas make it to the market - is another statistical fact.
How do those people who made developing novel therapies their mission make money on their way?
In this episode, I have the huge pleasure to chat with Thomas Schirrmann. He has profound experience in starting companies from scratch, walking through the ups and downs of Death V...
How is it to start a company from scratch, found it and fund it in the US, and get customers like the US Air Force and the Department of Defence.
In this episode, you will hear how Jessica Walsh, Founder, and CEO of RxBandz, one of the most successful women in life science in the world, did it.
In this episode, listen to Jessica’s stories about how to get into life science out of necessity, how it is to find the right team and develo...
We are the average of the five people we spent the most time with. Or are we the opposite?
Listen in this podcast episode how Daria Tataj sees it. Daria is THE number one networking expert in Europe.
Daria Tataj is a researcher, Ph.D., keynote speaker, author, and world expert on innovation networks.
After having reached more than 30.000 decision-makers around the world through her work helping companies, governments, and cities to...
Everybody comes in touch with the life science industry. Hardly anybody knew about the challenges, and hardships scientists have to overcome to bring a product from the university-level to the market.
Since the outbreak of SARS-CoV-2, more and more people are becoming interested in life science investments. And ask the question: How does that work?
In this episode, I am talking with entrepreneurs and investors from the LSG2G network....
The current pandemic shines a light on deep tech companies. Especially in life science. Did you ask yourself the question: What is necessary to bring a scientific idea from universities into companies and ultimately onto the market?
In this episode, I am talking with Klara Brandstätter and Jasmin Gungör. They are responsible for training, financing, and connecting deep-tech scientists.
What exactly they are doing, you will hear in t...
How to bring a scientific life science idea to patients?
Three key components are needed:
1. World-class science
2. World-class development team
3. Massive public and private funding
In this episode, I am talking with Michael Browne and Kimberly Cornfield on how to solve these three problems.
Reach out to Kimberly and Michael if you want to access their top-notch science networks within Crowdhelix and UCL.
Christian Soschner (ht...
The current pandemic SARS Cov 2 is shining a light on vaccine development. Since December 2019, the novel coronavirus is known amongst scientists. The virus is highly contagious. As a first measure, many governments all over the world have ordered a complete lockdown of the countries.
Some politicians make reverting life back to normal dependent on the existence of medication and/or vaccine. How long does it take to develop a vaccin...
Digital health is a technology that appeared only a few years ago. Up to now, it was very often overlooked. The current situation is helping digital health to show it's full potential. For example, Digital health can be used as a triage system, finding out first what kind of illness a patient has with chatbots and telemedicine solutions. Afterward, the patients can be referred to real-life doctors - to the right one.
A solution ...
Viral threats to humankind like the Coronavirus need scientists from all over the world collaborating to solve the problem. People like Saara Inkinen support scientists and universities to transfer their inventions to companies who turn science into products.
These products help patients to overcome illnesses and stay healthy. In this episode you will get some information how Saara helps in that area.
These days there is a lot of discussion about the development of diagnostics, therapeutics, and vaccines against the Coronavirus and it´s disease COVID 19. Viruses are one threat to the health of human beings. Bacteria is another one. Traditionally, bacterial infections are treated with antibiotics. Recently, some bacteria have developed antibiotic resistance.
The WHO describes that Antibiotic resistance is one of the biggest threat...
This week I had the honor to moderate a panel discussion at the RESI conference (https://www.resiconference.com/). It is one of the most important meetings for early-stage investment in the United States. Life Science Nation is the organizer of the event series. Last year in March the RESI conference visited Europe for the first time. The city of choice was Vienna. I invited Dennis Ford and Greg Mannix to visit the Life Science Get...
Michael Lukesch has recently closed his first financing round for Valanx Biotech. He started right after graduating into his entrepreneurial journey and cleared many obstacles on the way with excellence.
Valanx focuses on a novel approach for protein conjugation. Specific, fast, and cost-effective. The company is operating in lower Austria.
In the most recent episode of beginner's mind, Michael talks about how he brought himself ...